InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (19 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
19
T+90 hit rate
0%
T+90 mean return
-62.9%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Zalevsky Jonathan, Directeur de la Recherche et du Développement. Insider active across 2 companies, notably NEKTAR THERAPEUTICS. In total, 26 disclosures have been published. Breakdown: 0 buy · 19 sells. Total volume traded: €1.9m. Activity tracked since 17 May 2021. The latest transaction was filed on 19 May 2025 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations26 total
10,712 shares@ US$0.670.5% of flowCommon StockSEC:0000950170-25-075979:0
10,300 shares@ US$1.010.7% of flowCommon StockSEC:0000950170-25-025043:0
51,115 shares@ US$0.943.3% of flowCommon StockSEC:0000950170-24-139242:0
135,000 shares0Common StockSEC:0000950170-24-137545:0
7,785 shares@ US$1.010.5% of flowCommon StockSEC:0000950170-24-129463:0
6,866 shares@ US$1.280.6% of flowCommon StockSEC:0000950170-24-099354:0
7,355 shares@ US$1.750.9% of flowCommon StockSEC:0000950170-24-062645:0
9,014 shares@ US$0.680.4% of flowCommon StockSEC:0000950170-24-019045:0
9,646 shares@ US$0.490.3% of flowCommon StockSEC:0001209191-23-056184:0
9,703 shares@ US$0.780.5% of flowCommon StockSEC:0001209191-23-046462:0
9,791 shares@ US$0.720.5% of flowCommon StockSEC:0001209191-23-030448:0
10,484 shares@ US$3.002.1% of flowCommon StockSEC:0001209191-23-010956:0
13,460 shares@ US$3.573.3% of flowCommon StockSEC:0001209191-22-057968:0
73,716 shares@ US$4.6524.5% of flowCommon StockSEC:0001209191-22-046909:0
135,000 shares0Common StockSEC:0001209191-22-046489:0
23,950 shares0Common StockSEC:0001209191-22-029905:0
10,912 shares@ US$10.950.0044% mcap12.3% of flowCommon StockSEC:0001209191-22-011442:0
10,912 shares@ US$10.950.0044% mcap53.9% of flowCommon StockSEC:0001209191-22-011442
52,950 shares0Common StockSEC:0001209191-21-070697
52,950 shares0Common StockSEC:0001209191-21-070697:0
40,150 shares0Common StockSEC:0001209191-21-065229:0
40,150 shares0Common StockSEC:0001209191-21-065229
7,662 shares@ US$13.830.0038% mcap10.5% of flowCommon StockSEC:0001209191-21-052395:0
7,662 shares@ US$13.836.5% of flowCommon StockSEC:0001209191-21-052395
31,111 shares@ US$18.30100.0% of flowCommon StockSEC:0001209191-21-034191
25 of 26 declarations
About Zalevsky Jonathan
Jonathan Zalevsky is the Chief R&D Officer at Nektar Therapeutics. He is responsible for innovation and the development of new treatments within the company.
